dexmedetomidine altan pharma 4 mikrogram/ml infusionsvätska, lösning
altan pharma limited - dexmedetomidinhydroklorid - infusionsvätska, lösning - 4 mikrogram/ml - dexmedetomidinhydroklorid 4,727 mikrog aktiv substans; glukosmonohydrat hjälpämne
carbamazepine essential pharma 125 mg suppositorium
essential pharma (m) ltd - karbamazepin - suppositorium - 125 mg - karbamazepin 125 mg aktiv substans - karbamazepin
carbamazepine essential pharma 250 mg suppositorium
essential pharma (m) ltd - karbamazepin - suppositorium - 250 mg - karbamazepin 250 mg aktiv substans - karbamazepin
tetracyklin rph pharma 250 mg tablett
rph pharmaceuticals ab - tetracyklinhydroklorid - tablett - 250 mg - sackaros hjälpämne; tetracyklinhydroklorid 250 mg aktiv substans; laktosmonohydrat hjälpämne - tetracyklin
fingolimod unimedic pharma 0,5 mg kapsel, hård
unimedic pharma ab - fingolimodhydroklorid - kapsel, hård - 0,5 mg - fingolimodhydroklorid 0,56 mg aktiv substans
ribavirin teva pharma b.v.
teva b.v. - ribavirin - hepatit c, kronisk - antivirala medel för systemisk användning - ribavirin teva pharma b. is indicated in combination with other medicinal products for the treatment ofchronic hepatitis c (chc) in adults (see sections 4. 2, 4. 4 och 5. ribavirin teva pharma b. is indicated in combination with other medicinal products for the treatment ofchronic hepatitis c (chc) for paediatric patients (children 3 years of age and older and adolescents) notpreviously treated and without liver decompensation (see sections 4. 2, 4. 4 och 5.
mycophenolate mofetil cross pharma 500 mg filmdragerad tablett
cross pharma ab - mykofenolatmofetil - filmdragerad tablett - 500 mg - mykofenolatmofetil 500 mg aktiv substans
dasatinib accordpharma
accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastiska medel - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib. ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib. newly diagnosed ph+ all in combination with chemotherapy.
buprenorphine/naloxone g.l. pharma 8 mg/2 mg resoriblett, sublingual
g.l. pharma gmbh - buprenorfinhydroklorid; naloxonhydrokloriddihydrat - resoriblett, sublingual - 8 mg/2 mg - naloxonhydrokloriddihydrat 2,44 mg aktiv substans; buprenorfinhydroklorid 8,64 mg aktiv substans; laktosmonohydrat hjälpämne; mannitol hjälpämne
buprenorphine/naloxone g.l. pharma 4 mg/1 mg resoriblett, sublingual
g.l. pharma gmbh - buprenorfinhydroklorid; naloxonhydrokloriddihydrat - resoriblett, sublingual - 4 mg/1 mg - mannitol hjälpämne; laktosmonohydrat hjälpämne; naloxonhydrokloriddihydrat 1,22 mg aktiv substans; buprenorfinhydroklorid 4,32 mg aktiv substans